2026

VC-H1

Entrant

RAWGA Inc.

Category

Technology Solutions - Healthcare Solution

Client's Name

Hyunmin Kim

Country / Region

South Korea

VC-H1 is a clinically substantiated plant-based collagen peptide solution designed to redefine “beauty-from-within” wellness through cleaner sourcing, higher usability, and reproducible science. Produced from certified-organic Hibiscus sabdariffa through RAWGA’s proprietary extraction and enzymatic hydrolysis platform, VC-H1 addresses key limitations often associated with conventional collagen products—such as sensory challenges (odor/taste), formulation constraints, and the need for transparent, repeatable quality verification in global supply chains.

VC-H1 is not a simple amino acid blend. It features an ultra-low molecular weight (363 Da) tripeptide-rich profile, supporting efficient absorption compared with conventional collagen peptides (typically 1,000–5,000 Da). Its efficacy is supported by a robust 12-week randomized, double-blind, placebo-controlled human clinical trial (n=100) published in the International Journal of Molecular Sciences (2025). With daily supplementation of 1.5 g, the VC-H1 group showed statistically significant improvements in skin hydration and elasticity (R2, R5, R7), and a marked reduction in transepidermal water loss (TEWL) versus placebo (p < 0.001). 3D skin analysis further confirmed significant decreases in periorbital wrinkle depth and surface roughness (p < 0.001), validating meaningful anti-photoaging outcomes in consumer-relevant endpoints.

Mechanistically, VC-H1 delivers a dual-action approach—activating TGF-β1 signaling to stimulate Type I collagen synthesis while inhibiting MMP-1 activity linked to collagen degradation. As a botanical-derived collagen peptide, VC-H1 also naturally contains botanical antioxidants absent in animal collagen, quantified at Total Polyphenols 1,640 ppm (1.64 mg/g) and Total Flavonoids 11,240 ppm (11.24 mg/g), supporting oxidative-stress defense relevant to photoaging and skin-barrier resilience.

Built on a vertically integrated organic farm in Laos, RAWGA ensures 100% traceability and reinvests 3% of revenue into local farming communities. VC-H1 is more than an ingredient—it is a clinically proven, ethically sourced, traceable wellness solution setting a new benchmark for sustainable nutraceutical innovation.

Credits

CEO
Hyunmin Kim
Provider & Services
2026
A guide to smart serving and portion sizes, Healthcare Awards Winner

Entrant

American Kidney Fund

Category

Provider & Services - Health and Fitness

Country / Region

United States

Future Innovation Design
2026
Pro-EGT Compound Capsules, Healthcare Awards Winner

Entrant

HK Qian Yan International Trading Co., Limited

Category

Future Innovation Design - Product & Technology Design Innovation

Country / Region

Hong Kong SAR

Future Innovation Design
2026
Eegothioneine capsules, Healthcare Awards Winner

Entrant

Hong Kong Zhang Sheng Limited

Category

Future Innovation Design - Product Design

Country / Region

Hong Kong SAR

Social Media
2026
Faces of Innovation: Celebrating the People Behind Surgical Progress , Healthcare Awards Winner

Entrant

Asensus Surgical

Category

Social Media - Employee Engagement

Country / Region

United States